| Texto completo | |
| Autor(es): Mostrar menos - |
Scaramuzzi, Karina
;
Tanaka, Gabriela D.
;
Mariano Neto, Francisco
;
Garcia, Paulo R. A. F.
;
Gabrili, Joel J. M.
;
Oliveira, Denise C. A.
;
Tambourgi, Denise V.
;
Mussalem, Juliana S.
;
Paixao-Cavalcante, Danielle
;
D'Azeredo Orlando, Marcos T.
;
Botosso, Viviane F.
;
Oliveira, Cristiano L. P.
;
Fantini, Marcia C. A.
;
Sant'Anna, Osvaldo A.
Número total de Autores: 14
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Nanomedicine-Nanotechnology Biology and Medicine; v. 12, n. 8, p. 2241-2250, NOV 2016. |
| Citações Web of Science: | 4 |
| Resumo | |
Due to its physicochemical properties, nanostructured mesoporous SBA-15 silica shows great potential as a vaccine adjuvant. This study evaluated the capacity of SBA-15 to encapsulate/adsorb the recombinant purified HBsAg from the Hepatitis B virus and the immunoresponsiveness of mice orally immunized with HBsAg inside SBA-15. A simulation of small angle X-ray scattering experimental results, together with the nitrogen adsorption isotherms data, allowed to determine the appropriate mass ratio of HBsAg: SBA-15, indicating antigen encapsulation into SBA-15 macroporosity. This was also evaluated by bicinchoninic acid assay and gel electrophoresis. The recruitment of inflammatory cells, an increase in production of specific antibodies, and the non-influence of silica on TH1 or TH2 polarization were observed after oral immunization. Besides, SBA-15 enhanced the phagocytosis of ovalbumin by dendritic cells, an important key to prove how this adjuvant works. Thus, it seems clear that the nanostructured SBA-15 is an effective and safe adjuvant for oral immunizations. (C) 2016 Elsevier Inc. All rights reserved. (AU) | |
| Processo FAPESP: | 13/07467-1 - CeTICS - Centro de Toxinas, Imuno-Resposta e Sinalização Celular |
| Beneficiário: | Hugo Aguirre Armelin |
| Modalidade de apoio: | Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs |